Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults

INTRODUCTION: Respiratory syncytial virus (RSV) infection causes respiratory disease throughout life, with infants and the elderly at risk of severe disease and death. RSV001 is a phase 1 (first-in-man), open-label, dose-escalation, clinical trial of novel genetic viral-vectored vaccine candidates P...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, C A, Scarselli, E, Voysey, M, Capone, S, Vitelli, A, Nicosia, A, Cortese, R, Thompson, A J, Sande, C S, de Lara, Catherine, Klenerman, P, Pollard, A J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Infectious Diseases
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636663/
https://www.ncbi.nlm.nih.gov/pubmed/26510727
http://dx.doi.org/10.1136/bmjopen-2015-008748

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636663/
https://www.ncbi.nlm.nih.gov/pubmed/26510727
http://dx.doi.org/10.1136/bmjopen-2015-008748

Ejemplares similares